RT001 ( DrugBank: - )


3 diseases
IDDisease name (Link within this page)Number of trials
2Amyotrophic lateral sclerosis4
5Progressive supranuclear palsy5
120Hereditary dystonia1

2. Amyotrophic lateral sclerosis


Clinical trials : 624 Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-003962-38-SE
(EUCTR)
21/08/202105/11/2020A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLERABILITY OF RT001 IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSISA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLERABILITY OF RT001 IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS Amyotrophic Lateral Sclerosis
MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: RT001
Product Code: RT001
INN or Proposed INN: Not assigned
Other descriptive name: 9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER
Retrotope, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
44Phase 2Estonia;Netherlands;Sweden
2NCT04762589
(ClinicalTrials.gov)
March 10, 202117/2/2021RT001 in Amyotrophic Lateral SclerosisA Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisDrug: RT001;Drug: PlaceboRetrotope, Inc.NULLRecruiting20 Years75 YearsAll40Phase 2Sweden;Netherlands;Latvia;Estonia
3EUCTR2020-003962-38-NL
(EUCTR)
18/02/202118/01/2021A DOUBLE BLIND, PLACEBO-CONTROLLED, STUDY OF RT001 TREATMENT, FOR PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSISA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLERABILITY OF RT001 IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS Amyotrophic Lateral Sclerosis
MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: RT001
Product Code: RT001
INN or Proposed INN: Not assigned
Other descriptive name: 9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER
Retrotope, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
44Phase 2Estonia;Netherlands;Sweden
4EUCTR2020-003962-38-EE
(EUCTR)
02/02/202103/11/2020A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLERABILITY OF RT001 IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSISA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLERABILITY OF RT001 IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS Amyotrophic Lateral Sclerosis
MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: RT001
Product Code: RT001
INN or Proposed INN: Not assigned
Other descriptive name: 9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER
Retrotope, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
44Phase 2Estonia;Netherlands;Sweden

5. Progressive supranuclear palsy


Clinical trials : 95 Drugs : 119 - (DrugBank : 40) / Drug target genes : 65 - Drug target pathways : 108
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04937530
(ClinicalTrials.gov)
June 23, 202116/6/2021RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSYA Randomized, Double-blind, Controlled, Phase 2 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: RT001;Drug: PlaceboRetrotope, Inc.NULLRecruiting40 Years80 YearsAll40Phase 2Germany
2EUCTR2020-003911-90-PL
(EUCTR)
07/05/202120/04/2021A RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLERABILITY OF RT001 IN SUBJECTS WITH PROGRESSIVE SUPRANUCLEAR PALSY. A RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLERABILITY OF RT001 IN SUBJECTS WITH PROGRESSIVE SUPRANUCLEAR PALSY. Progressive supranuclear palsy (PSP)
MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: RT001
Product Code: RT001
INN or Proposed INN: not assigned
Other descriptive name: 9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER
Retrotope, IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
40Phase 2Hungary;Slovakia;Poland;Germany
3EUCTR2020-003911-90-DE
(EUCTR)
31/03/202130/11/2020A RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLERABILITY OF RT001 IN SUBJECTS WITH PROGRESSIVE SUPRANUCLEAR PALSY. A RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLERABILITY OF RT001 IN SUBJECTS WITH PROGRESSIVE SUPRANUCLEAR PALSY. Progressive supranuclear palsy (PSP)
MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: RT001
Product Code: RT001
INN or Proposed INN: not assigned
Other descriptive name: 9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER
Retrotope, IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Phase 2Hungary;Slovakia;Poland;Germany
4EUCTR2020-003911-90-SK
(EUCTR)
23/03/202113/01/2021A study to learn how well the drug RT001 works and how safe RT001 is in people who have progressive supranuclear palsy. A RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLERABILITY OF RT001 IN SUBJECTS WITH PROGRESSIVE SUPRANUCLEAR PALSY. Progressive supranuclear palsy (PSP)
MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: RT001
Product Code: RT001
INN or Proposed INN: not assigned
Other descriptive name: 9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER
Retrotope, IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
40Phase 2Hungary;Slovakia;Poland;Germany
5EUCTR2020-003911-90-HU
(EUCTR)
19/02/202109/12/2020A RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLERABILITY OF RT001 IN SUBJECTS WITH PROGRESSIVE SUPRANUCLEAR PALSY. A RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLERABILITY OF RT001 IN SUBJECTS WITH PROGRESSIVE SUPRANUCLEAR PALSY. Progressive supranuclear palsy (PSP)
MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: RT001
Product Code: RT001
INN or Proposed INN: not assigned
Other descriptive name: 9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER
Retrotope, IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Phase 2Hungary;Slovakia;Poland;Germany

120. Hereditary dystonia


Clinical trials : 25 Drugs : 21 - (DrugBank : 4) / Drug target genes : 2 - Drug target pathways : 2
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03570931
(ClinicalTrials.gov)
November 5, 201811/6/2018A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal DystrophyA Prospective Open-label Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal DystrophyInfantile Neuroaxonal DystrophyDrug: RT001Retrotope, Inc.NULLActive, not recruiting18 Months10 YearsAll19Phase 2/Phase 3United States